28 October 2022 10:00–15:00: POSTER SESSION: Novel Clinical Trial Design359 (PB139) - Response to neoadjuvant targeted therapy in operable head and neck cancer confers survival benefit
References (0)
Cited by (0)
Copyright © 2022 Elsevier Ltd. All rights reserved. Published by Elsevier Ltd. All rights reserved.